The Claim

In adults with MASLD without type 2 diabetes, liraglutide therapy reduces de novo lipogenesis (DNL) more than matched lifestyle-induced weight loss during active treatment, and DNL rebounds significantly after discontinuation in both groups, indicating that suppression of liver fat production is not sustained after weight loss ends.

Source: Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
68score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

In adults with MASLD but without type 2 diabetes, liraglutide reduces liver fat production more than weight loss from lifestyle changes while treatment is ongoing, but liver fat production increases again after stopping treatment in both groups, showing that the reduction in liver fat production does not last after treatment ends.

See the scientific wording

In adults with MASLD without type 2 diabetes, liraglutide therapy reduces de novo lipogenesis (DNL) more than matched lifestyle-induced weight loss during active treatment, but DNL rebounds significantly after discontinuation in both groups, indicating that suppression of liver fat production is not sustained after weight loss ends.

Why this might work

Liraglutide activates receptors that make the pancreas release more insulin when blood sugar rises, which helps the body use glucose more efficiently. This lowers the amount of sugar available for the liver to turn into fat. When liraglutide stops, insulin response weakens, glucose builds up again, and the liver resumes making fat at high rates. At the same time, fat tissue becomes inflamed and sends signals that further disrupt metabolism, accelerating fat production in the liver.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD

    Liraglutide lowered liver fat production more than dieting while people were taking it, but once they stopped either treatment, liver fat production went back up in everyone. So, stopping any weight-loss method leads to a rebound.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.